ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2282

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices

Sarah Ringold1, George A. Tomlinson2, Pamela F. Weiss3, Laura E. Schanberg4, Brian M. Feldman5, Mary Ellen Riordan6, Anne C. Dennos7, Vincent Del Gaizo8, Katherine Murphy9 and Yukiko Kimura6, 1Seattle Children's Hospital, Seattle, WA, 2Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 4Pediatrics, Duke University Medical Center, Durham, NC, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Hackensack University Medical Center, Hackensack, NJ, 7Duke Clinical Research Institute, Durham, NC, 8Parent Partner, Whitehouse Station, NJ, 9Parent Partner, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Comparative effectiveness and harms, Juvenile Arthritis, juvenile idiopathic arthritis (JIA) and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite the many available new and effective treatments for polyarticular JIA (P-JIA), there is significant variation in the timing of when biologic medications are started. Three consensus treatment plans (CTPs) reflecting the currently most commonly-used strategies for starting biologic treatment were developed by the Childhood Arthritis and Rheumatology Research Alliance (CARRA) using consensus methodology.  The CARRA Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) study aims to compare the effectiveness of the 3 CARRA P-JIA CTPs using a prospective, observational study design. This abstract describes interim baseline characteristics and CTP choices for the patients enrolled in STOP-JIA.

Methods: Untreated P-JIA patients were enrolled into the CARRA Registry. Providers and patients together chose one of the CTPs to follow: 1) Step-Up treatment (initial therapy with DMARD and biologic added after 3 months if needed); 2) Early Combination (initial therapy with both DMARD and biologic); and 3) Biologic First (initial treatment with biologic monotherapy). Providers had the option of prescribing glucocorticoids at baseline per their usual practice and were provided with tapering options. There is no randomization or blinding in this observational study. 

Results: One hundred and eighty two patients were enrolled at 37 sites in the US and Canada between 1 Nov 15 and 31 May 17. Patient characteristics are summarized in Table 1. The most commonly chosen CTP was Step-Up (n=116; 64%). Early Combination CTP was the next most common choice (n=44; 24%). Forty eight (26%) of patients received oral steroids at baseline. To date, 491 follow up visits have been entered and 30 patients have completed their 12 month visit. Of the patients who have completed their 3 month visit, 10 patients were reported to have changed CTP. There were 9 Serious Adverse Events (SAE) or Important Medical Events (IME): 1 each of septic shock (CTCAE Grade 3), influenza A (Grade 2), new onset uveitis (Grade 2), shingles (Grade 2), seizure (Grade 1), hepatitis (Grade 1), and 3 infections treated with IV antibiotics (Grades 1 , 2, and 3).

Conclusion: To date, patients have been enrolled into all 3 CTP choices, with the Step-Up CTP being the most common. Ongoing, prospective data collection from these patients will allow for a comparison of the effectiveness of the strategies.

Table 1. Baseline Patient Characteristics

 

Total Cohort (n=182)

Step up (n=116)

Early Combination (n=44)

Biologic First (n=22)

Female N (%)

134 (74%)

85 (76%)

31 (71%)

15 (68%)

White N (%)

118 (69%)

85 (73%)

28 (64%)

13 (59%)

Age in yrs – median (IQR)*

11 (6, 14)

11 (6, 14)

11 (8, 14)

13 (7, 15)

JIA Category

N (%)

 

 

 

 

Extended Oligoarticular

2 (1)

2 (2)

—

—

Polyarticular (RF-)                                                

121 (67)

88 (76)

23 (52)

10 (46)

Polyarticular (RF+)

27 (15)

14 (12)

12 (27)

1 (5)

Psoriatic

9 (5)

4 (3)

2 (5)

3 (14)

Enthesitis-related

19 (10)

8 (7)

5 (11)

6 (27)

Undifferentiated

4 (2)

—

2 (5)

2 (9)

Number of Active joints – median (IQR)

9 (6, 17)

14 (8, 22)

8 (6, 13))

8 (6, 15)

Physician Global Assessment of Disease Activity – median (IQR)

5 (4, 7)

5 (4, 7)

7 (5, 8)

6 (5, 8)

Juvenile Arthritis Disease Activity Score – median (IQR)

18 (15, 22)

17 (14, 20)

21 (17, 23)

19 (17, 22)

CHAQ Score – median (IQR)

1 (0, 1.5)

0.6 (0.2, 1.2)

1 (0.6, 2.5)

0.9 (0.6, 2.1)

Oral steroids prescribed at baseline – N (%)

48 (26%)

31 (27)

15 (34)

2 (9)

* IQR: Interquartile Range

 



Disclosure: S. Ringold, Crescendo Bioscience, 2; G. A. Tomlinson, None; P. F. Weiss, Eli Lilly and Company, 5; L. E. Schanberg, Sanofi, Swedish Orphan Biovitrum, 9; B. M. Feldman, None; M. E. Riordan, None; A. C. Dennos, None; V. Del Gaizo, Sobi, 5; K. Murphy, None; Y. Kimura, None.

To cite this abstract in AMA style:

Ringold S, Tomlinson GA, Weiss PF, Schanberg LE, Feldman BM, Riordan ME, Dennos AC, Del Gaizo V, Murphy K, Kimura Y. The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-childhood-arthritis-and-rheumatology-research-alliance-start-time-optimization-of-biologic-therapy-in-polyarticular-jia-study-interim-report-of-baseline-patient-characteristics-and-treatment-choi/. Accessed January 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-childhood-arthritis-and-rheumatology-research-alliance-start-time-optimization-of-biologic-therapy-in-polyarticular-jia-study-interim-report-of-baseline-patient-characteristics-and-treatment-choi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.